SUSBSEQUENT EVENTS |
9 Months Ended | ||
|---|---|---|---|
Sep. 30, 2020 | |||
| Subsequent Events [Abstract] | |||
| SUSBSEQUENT EVENTS |
On September 8, 2020, the Company announced data from its Phase 3 study of lenabasum for treatment of systemic sclerosis and announced that the study showed no significant differences in the primary and secondary endpoints when comparing lenabasum to placebo. On October 6, 2020, the Company announced its Phase 2b Study of lenabasum for treatment of cystic fibrosis did not meet its primary end point. On October 8, 2020, the Company announced plans to reduce its workforce by approximately 54% and expects to incur a charge of approximately $3,000,000 related to severance, benefits and related costs, substantially all of which will be recorded in the fourth quarter of 2020. |